Vertex Under Pressure To Spend On M&A
Company Has $6.7bn In Cash
Executive Summary
The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development
You may also be interested in...
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.